U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C3H5O3.Na
Molecular Weight 112.0598
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM LACTATE, L-

SMILES

[Na+].C[C@H](O)C([O-])=O

InChI

InChIKey=NGSFWBMYFKHRBD-DKWTVANSSA-M
InChI=1S/C3H6O3.Na/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);/q;+1/p-1/t2-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C3H5O3
Molecular Weight 89.07
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9BXC0
Gene ID: 27198.0
Gene Symbol: HCAR1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PRISMASOL

Approved Use

PRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances.

Launch Date

1.16164801E12
PubMed

PubMed

TitleDatePubMed
High resolution 1H n.m.r. studies of vertebrate blood and plasma.
1983 Jun 1
Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls.
1988 Feb
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate.
1991 May
Standardized method for high-resolution 1H-NMR of cerebrospinal fluid.
1995 May
Asymmetric intramolecular [2 + 2] photocycloadditions: alpha- and beta-hydroxy acids as chiral tether groups.
2002 Feb 22
Asymmetric total synthesis of (+)-brefeldin A from (S)-lactate by triple chirality transfer process and nitrile oxide cycloaddition.
2002 Feb 8
1H and (13)C NMR spectroscopic analysis of human saliva.
2002 Jun
Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst.
2003 Dec 12
Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31.
2003 Oct 24
Asymmetric intermolecular C-H functionalization of benzyl silyl ethers mediated by chiral auxiliary-based aryldiazoacetates and chiral dirhodium catalysts.
2005 Dec 23
Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition.
2005 May 9
Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
2006 Jan
Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder.
2007 Jan 15
Facile alcoholysis of L-lactide catalysed by Group 1 and 2 metal complexes.
2008 Jun 21
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81.
2010 Apr 7
Patents

Sample Use Guides

Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:08 UTC 2023
Edited
by admin
on Fri Dec 15 15:13:08 UTC 2023
Record UNII
P2Y1C6M9PS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM LACTATE, L-
II  
Common Name English
SODIUM (S)-LACTATE SOLUTION
Common Name English
SODIUM (S)-LACTATE SOLUTION [EP MONOGRAPH]
Common Name English
SODIUM L-LACTATE [JAN]
Common Name English
SODIUM L-LACTATE
Common Name English
SODIUM-L-LACTATE
Common Name English
Sodium L-lactate [WHO-DD]
Common Name English
(S)-2-HYDROXYPROPANOIC ACID MONOSODIUM SALT
Common Name English
SODIUM (S)-LACTATE
Systematic Name English
SODIUM LACTATE, (S)-
Common Name English
SODIUM LACTATE, L- [II]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29730
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
Code System Code Type Description
EVMPD
SUB36522
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
CAS
867-56-1
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID5052830
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
DAILYMED
P2Y1C6M9PS
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
NCI_THESAURUS
C61944
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
SMS_ID
100000128870
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
PUBCHEM
23664767
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
FDA UNII
P2Y1C6M9PS
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
212-762-3
Created by admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE